keyword
MENU ▼
Read by QxMD icon Read
search

Liraglutide

keyword
https://www.readbyqxmd.com/read/29145215/comparison-of-efficacy-and-safety-of-liraglutide-3-0-mg-in-individuals-with-bmi-above-and-below-35-kg-m%C3%A2-a-post-hoc-analysis
#1
Carel le Roux, Vanita Aroda, Joanna Hemmingsson, Ana Paula Cancino, Rune Christensen, Xavier Pi-Sunyer
OBJECTIVE: To investigate whether the efficacy and safety of liraglutide 3.0 mg differed between two subgroups, BMI 27 to <35 and BMI ≥ 35 kg/m², in individuals without and with type 2 diabetes (T2D). METHODS: A post-hoc analysis of two 56-week, randomized, double-blind, placebo-controlled trials (SCALE Obesity and Prediabetes; SCALE Diabetes). Subgroup differences in treatment effects of liraglutide 3.0 mg were evaluated by testing the interaction between treatment group and baseline BMI subgroup...
November 17, 2017: Obesity Facts
https://www.readbyqxmd.com/read/29139081/liraglutide-improves-cardiovascular-risk-as-an-add-on-to-metformin-and-not-to-insulin-secretagogues-in-type-2-diabetic-patients-a-real-life-48-month-retrospective-study
#2
Alessandro Ciresi, Enrica Vigneri, Stefano Radellini, Felicia Pantò, Carla Giordano
INTRODUCTION: Although liraglutide is widely recognized to have glycemic and extra-glycemic effects, few studies have compared these effects in relation to hypoglycemic treatment starting from the diagnosis of diabetes. We evaluated the effectiveness of liraglutide in reducing the Framingham risk score (FRS) and visceral adiposity index (VAI) in relation to first-line hypoglycemic treatment from diagnosis of type 2 diabetes, continued without any changes. METHODS: We selected 105 diabetic outpatients who were treated with liraglutide for at least 48 months as an add-on therapy to metformin alone (group A, n = 52) or insulin secretagogues (group B, n = 53) from diagnosis time...
November 14, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29133778/glucagon-like-peptide-1-glp-1-receptor-agonist-liraglutide-alters-bone-marrow-exosome-mediated-mirna-signal-pathways-in-ovariectomized-rats-with-type-2-diabetes
#3
Jin Li, Ling-Zhi Fu, Lu Liu, Fen Xie, Ru-Chun Dai
BACKGROUND Compared with normal postmenopausal women, estrogen deficiency and hyperglycemia in postmenopausal women with type 2 diabetes (T2DM) lead to more severe bone property degradation. Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been reported to improve bone condition among people with T2DM but the precise mechanisms remain unclear. Exosomes work as mediators in cell-to-cell communication, delivering functional miRNAs between cells. We aimed to explore the role of exosomes in T2DM-related bone metabolic disorders and the bone protective mechanisms of liraglutide...
November 14, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/29128056/emerging-treatments-for-nonalcoholic-fatty-liver-disease-and-nonalcoholic-steatohepatitis
#4
REVIEW
Samer Gawrieh, Naga Chalasani
This review discusses completed phase II randomized clinical trials with high-quality published results for compounds that demonstrate effects on nonalcoholic steatohepatitis histology (obeticholic acid, elafibranor, and liraglutide). The authors also review the available preliminary data on cenicriviroc and selonsertib, with or without simtuzumab's phase II studies. Finally, the authors briefly discuss compounds that have been tested but did not achieve the primary end point of histologic improvement and appeared in high-quality published articles (cysteamine bitartrate and long-chain polyunsaturated fatty acids)...
February 2018: Clinics in Liver Disease
https://www.readbyqxmd.com/read/29119245/development-and-characterisation-of-a-novel-glucagon-like-peptide-1-receptor-antibody
#5
Emma K Biggs, Lihuan Liang, Jacqueline Naylor, Shimona Madalli, Rachel Collier, Matthew P Coghlan, David J Baker, David C Hornigold, Peter Ravn, Frank Reimann, Fiona M Gribble
AIMS/HYPOTHESIS: Glucagon like peptide-1 (GLP-1) enhances glucose-dependent insulin secretion by binding to GLP-1 receptors (GLP1Rs) on pancreatic beta cells. GLP-1 mimetics are used in the clinic for the treatment of type 2 diabetes, but despite their therapeutic success, several clinical effects of GLP-1 remain unexplained at a mechanistic level, particularly in extrapancreatic tissues. The aim of this study was to generate and characterise a monoclonal antagonistic antibody for the GLP1R for use in vivo...
November 9, 2017: Diabetologia
https://www.readbyqxmd.com/read/29110715/liraglutide-dictates-macrophage-phenotype-in-apolipoprotein-e-null-mice-during-early-atherosclerosis
#6
Robyn Bruen, Sean Curley, Sarina Kajani, Daniel Crean, Marcella E O'Reilly, Margaret B Lucitt, Catherine G Godson, Fiona C McGillicuddy, Orina Belton
BACKGROUND: Macrophages play a pivotal role in atherosclerotic plaque development. Recent evidence has suggested the glucagon-like peptide-1 receptor (GLP-1R) agonist, liraglutide, can attenuate pro-inflammatory responses in macrophages. We hypothesized that liraglutide could limit atherosclerosis progression in vivo via modulation of the inflammatory response. METHODS: Human THP-1 macrophages and bone marrow-derived macrophages, from both wild-type C57BL/6 (WT) and apolipoprotein E null mice (ApoE(-/-)) were used to investigate the effect of liraglutide on the inflammatory response in vitro...
November 6, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/29110598/sirt1-as-a-therapeutic-target-in-diabetic-complications
#7
Justyna Strycharz, Żaneta Rygielska, Ewa Świderska, Józef Drzewoski, Janusz Szemraj, Leszek Szmigiero, Agnieszka Śliwińska
Background SIRT1 is an epigenetic enzyme involved in histone and non-histone protein deacetylation. It acts primarily as a metabolic sensor, which responses to changing energy status by deacetylating crucial transcription factors and cofactors. In this way, SIRT1 regulates mitochondrial function and biogenesis, oxidative stress, inflammation, apoptosis and cellular senescence. Disturbance of all of these phenomena promotes the pathogenesis of diabetic complications. These disorders are inseparably connected with chronic hyperglycemia, which possesses a strong epigenetic determinant...
November 6, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29107282/the-autonomic-nervous-system-and-cardiac-glp-1-receptors-control-heart-rate-in-mice
#8
Laurie L Baggio, John R Ussher, Brent A McLean, Xiemin Cao, M Golam Kabir, Erin E Mulvihill, Alexandra S Mighiu, Hangjun Zhang, Andreas Ludwig, Randy J Seeley, Scott P Heximer, Daniel J Drucker
OBJECTIVES: Glucagon-like peptide-1 (GLP-1) is secreted from enteroendocrine cells and exerts a broad number of metabolic actions through activation of a single GLP-1 receptor (GLP-1R). The cardiovascular actions of GLP-1 have garnered increasing attention as GLP-1R agonists are used to treat human subjects with diabetes and obesity that may be at increased risk for development of heart disease. Here we studied mechanisms linking GLP-1R activation to control of heart rate (HR) in mice...
November 2017: Molecular Metabolism
https://www.readbyqxmd.com/read/29106046/retrospective-analysis-of-liraglutide-and-basal-insulin-combination-therapy-in-japanese-type-2-diabetes-the-association-between-remaining-%C3%AE-cell-function-and-the-achievement-of-the-hba1c-target-one-year-after-initiation
#9
Ryota Usui, Yui Sakuramachi, Yusuke Seino, Kenta Murotani, Hitoshi Kuwata, Hisato Tatsuoka, Yoshiyuki Hamamoto, Takeshi Kurose, Yutaka Seino, Daisuke Yabe
BACKGROUND AND AIMS: The glucose-lowering effects of the GLP-1 receptor agonist liraglutide have been shown to rely on remaining β-cell function. However, the possible associations of remaining β-cell function with the glucose-lowering effects of liraglutide in combination with basal insulin remain unknown and warrant investigation. METHODS: This is a single-center, retrospective, observational study conducted in a private hospital in Osaka, Japan. Type 2 diabetes patients who received a prescription change from insulin therapy, both multiple-dose insulin (MDI) and basal insulin-supported oral therapy (BOT), to liraglutide/basal insulin combination and continued the therapy for 54 weeks without additional oral anti-diabetic drugs (OAD) or bolus insulin were retrospectively analyzed...
November 6, 2017: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/29090600/comparison-between-insulin-degludec-liraglutide-treatment-and-insulin-glargine-lixisenatide-treatment-in-type-2-diabetes-a-systematic-review-and-meta-analysis
#10
Xiaoling Cai, Xueying Gao, Wenjia Yang, Linong Ji
AIM: To evaluate the efficacy and adverse effects of IDegLira and IGlarLixi treatment and to perform a comparison between two strategies. METHODS: The registration number is CRD42017053952. Randomized controlled trials of IGlarLixi treatment or IDegLira treatment compared with placebo or active hypoglycemic agents in type 2 diabetes were included. RESULTS: Eight trials were included. The absolute HbA1c change relative to baseline after IGlarLixi treatment was -1...
November 1, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29083275/albiglutide-efficacy-and-safety-in-the-latino-hispanic-subpopulation-for-the-integrated-phase-iii-program
#11
Jaime A Davidson, Angela Jones-Leone, Timothy H Wilson, Antonio Nino, Sergio Forero-Schwanhaeuser, Rickey R Reinhardt
OBJECTIVE: to evaluate the efficacy and safety of albiglutide compared with placebo and active comparators from an integrated trial subpopulation of Latino/Hispanic patients whose type 2 diabetes mellitus (T2DM) was inadequately controlled on their current regimen of diet and exercise, with or without oral antidiabetic drugs (OADs) and/or insulin. METHODS: Latino/Hispanic patient subpopulations (N = 1204) across 7 phase III albiglutide studies (N = 4400) were evaluated post-hoc for efficacy and safety...
October 30, 2017: Postgraduate Medicine
https://www.readbyqxmd.com/read/29080210/cost-effectiveness-of-exenatide-once-weekly-versus-insulin-glargine-and-liraglutide-for-the-treatment-of-type-2-diabetes-mellitus-in-greece
#12
Charalampos Tzanetakos, Alexandra Bargiota, Georgia Kourlaba, George Gourzoulidis, Nikos Maniadakis
OBJECTIVE: The objective of this study was to evaluate the long-term cost effectiveness of exenatide once weekly (ExQW) versus insulin glargine (IG) or liraglutide 1.2 mg (Lira1.2mg) for the treatment of adult patients with type 2 diabetes mellitus (T2DM) not adequately controlled on oral antidiabetic drug (OAD) therapy in Greece. METHODS: The published and validated Cardiff Diabetes Model was used to project clinical and economic outcomes over a patient's lifetime...
October 27, 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29076038/long-term-effectiveness-of-liraglutide-in-association-with-patients-baseline-characteristics-in-real-life-setting-in-croatia-an-observational-retrospective-multicenter-study
#13
Maja Cigrovski Berkovic, Ines Bilic-Curcic, Davorka Herman Mahecic, Marina Gradiser, Mladen Grgurevic, Tomislav Bozek
INTRODUCTION: Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are recommended therapy for type 2 diabetes (T2DM) and liraglutide is the most used worldwide. We assessed the glycemic efficacy and extra-glycemic effects of liraglutide during 36 months' follow-up of individuals with poorly regulated T2DM under routine clinical practice and sought to identify the phenotype of treatment responders. METHODS: A total of 207 individuals were included. The primary endpoint was the proportion of participants with HbA1c < 7...
December 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29069819/comparison-of-twelve-single-drug-regimens-for-the-treatment-of-type-2-diabetes-mellitus
#14
Shao-Lian Wang, Wen-Bin Dong, Xiao-Lin Dong, Wen-Min Zhu, Fang-Fang Wang, Fang Han, Xin Yan
We performed a network meta-analysis to compare the efficacy of 12 single-drug regimens (Glibenclamide, Glimepiride, Pioglitazone, Rosiglitazone, Repaglinide, Metformin, Sitaglitin, Exenatide, Liraglutide, Acarbose, Benfluorex, and Glipizide) in the treatment of type 2 diabetes mellitus (T2DM). Fifteen relevant randomized controlled trials (RCTs) were included; direct and indirect evidence from these studies was combined, and weighted mean difference (WMD) and surface under the cumulative ranking curves (SUCRAs) were examined to evaluate the monotherapies...
September 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/29067421/liraglutide-may-reduce-diabetic-kidney-disease
#15
Anita Slomski
No abstract text is available yet for this article.
October 24, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/29065174/glucagon-like-receptor-1-glucagon-dual-agonist-acutely-enhanced-hepatic-lipid-clearance-and-suppressed-de-novo-lipogenesis-in-mice
#16
Vijay R More, Julie Lao, David G McLaren, Anne-Marie Cumiskey, Beth Ann Murphy, Ying Chen, Stephen Previs, Steven Stout, Rajesh Patel, Santhosh Satapati, Wenyu Li, Edward Kowalik, Daphne Szeto, Andrea Nawrocki, Alessandro Pocai, Liangsu Wang, Paul Carrington
Lipid lowering properties of glucagon have been reported. Blocking glucagon signaling leads to rise in plasma LDL levels. Here, we demonstrate the lipid lowering effects of acute dosing with Glp1r/Gcgr dual agonist (DualAG). All the experiments were performed in 25 week-old male diet-induced (60% kCal fat) obese mice. After 2 hrs of fasting, mice were injected subcutaneously with vehicle, liraglutide (25nmol/kg) and DualAG (25nmol/kg). De novo cholesterol and palmitate synthesis was measured by deuterium incorporation method using D2O...
2017: PloS One
https://www.readbyqxmd.com/read/29064743/dipeptidyl-peptidase-4-inhibitor-sitagliptin-prevented-weight-regain-in-obese-women-with-polycystic-ovary-syndrome-previously-treated-with-liraglutide-a-pilot-randomized-study
#17
Simona Ferjan, Andrej Janez, Mojca Jensterle
BACKGROUND: Weight loss is often nonsustainable after liraglutide cessation. The present study is the first insight into the potential prevention of weight regain in obese subjects who have been withdrawn from liraglutide. We evaluated whether dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin in adjunct to metformin prevents body weight regain more effectively than metformin alone in obese polycystic ovary syndrome (PCOS) previously treated with liraglutide. METHODS: A 12-week prospective randomized open-label study was conducted with 24 obese women with PCOS who had been pretreated with liraglutide 3...
October 24, 2017: Metabolic Syndrome and related Disorders
https://www.readbyqxmd.com/read/29063511/cost-effectiveness-of-ideglira-versus-insulin-intensification-regimens-for-the-treatment-of-adults-with-type-2-diabetes-in-the-czech-republic
#18
Milan Kvapil, Martin Prázný, Pavel Holik, Karel Rychna, Barnaby Hunt
INTRODUCTION: The aim of this study was to evaluate the long-term cost-effectiveness of the insulin degludec/liraglutide combination (IDegLira) versus basal insulin intensification strategies for patients with type 2 diabetes mellitus (T2DM) not optimally controlled on basal insulin in the Czech Republic. METHODS: Cost-effectiveness was evaluated using the QuintilesIMS Health CORE Diabetes model, an interactive internet-based model that simulates clinical outcomes and costs for cohorts of patients with diabetes...
December 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29045079/improvements-in-health-related-quality-of-life-over-3%C3%A2-years-with-liraglutide-3-0%C3%A2-mg-compared-with-placebo-in-participants-with-overweight-or-obesity
#19
R L Kolotkin, B Gabriel Smolarz, H H Meincke, K Fujioka
Previously in the SCALE Obesity and Prediabetes trial, at 1 year, participants with obesity (or overweight with comorbidities) and prediabetes receiving liraglutide 3.0 mg experienced greater improvements in health-related quality of life (HRQoL) than those receiving placebo. The current study extends these findings by examining 3-year changes in HRQoL. HRQoL was assessed using the obesity-specific Impact of Weight on Quality of Life-Lite (IWQOL-Lite) questionnaire, as well as the Short-Form 36 v2 (SF-36) health survey...
October 16, 2017: Clinical Obesity
https://www.readbyqxmd.com/read/29044799/insulin-secretory-defect-in-familial-partial-lipodystrophy-type-2-and-successful-long-term-treatment-with-a-glucagon-like-peptide-1-receptor-agonist
#20
F Banning, M Rottenkolber, I Freibothe, J Seissler, A Lechner
BACKGROUND: Familial partial lipodystrophies are rare monogenic disorders that are often associated with diabetes. In such cases, it can be difficult to achieve glycaemic control. CASE REPORT: We report a 34-year old woman with familial partial lipodystrophy type 2 (Dunnigan) and diabetes; her hyperglycaemia persisted despite metformin treatment. A combined intravenous glucose tolerance-euglycaemic clamp test showed severe insulin resistance, as expected, but also showed strongly diminished first-phase insulin secretion...
October 17, 2017: Diabetic Medicine: a Journal of the British Diabetic Association
keyword
keyword
20037
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"